Although the treatment of myeloma has changed dramatically after the readout of many recent trials, key unanswered questions remain.

Multiple myeloma ... and harm your kidneys. Myeloma cells crowd out normal blood cells, lowering your red blood cell count, causing anemia and fatigue. Without treatment, these cells continue ...

Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has ...

Ospomyv, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Xbryk, a ...

A five-year study has found that adding daratumumab (D) to the current standard-of-care triplet therapy bortezomib, lenalidomide, and dexamethasone (VRd) produced deeper and more durable minimal ...

According to Binod Dhakal of the Medical College of Wisconsin, one of the study investigators, the approval gives patients the opportunity for a treatment-free period for their multiple myeloma as ...

The Committee for Medicinal Products for Human Use (CHMP) recommended expansion of the Carvykti label to include adult patients with relapsed and refractory multiple myeloma, who have received at ...

So, we now have multiple new classes of drugs, multiple agents that are FDA-approved for the treatment of multiple myeloma, more than 15, 16 different drugs that have become available in that period.

During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to ...

The phase 2 REST trial by Frida Bugge Askeland and colleagues, reported in The Lancet Haematology, provides insight into optimising anti-CD38 antibody-containing quadruplet regimens (quads) for ...